BMI OrganBank, a company specializing in integrated organ preservation and assessment systems, has released preclinical data evaluating its OrganBank Kidney platform. The platform uses a distinctive bloodless, oxygenated, pulsatile machine perfusion process at room temperature to preserve and assess kidneys. The results were presented at the 2026 American Society of Transplant Surgeons Winter Symposium by Dr. Nader Abraham, Vice President of Research at BMI OrganBank and a resident in General and Transplant Surgery at Duke University. In a porcine kidney auto-transplant model conducted at Duke University’s Ex-Vivo Organ Lab, kidneys preserved using standard hypothermic unoxygenated machine preservation experienced delayed graft function in 40 percent of cases. In contrast, kidneys preserved with the OrganBank Kidney platform showed no delayed graft function and demonstrated immediate early graft performance.
Health Technology Insights: Steven Gonzalez on Leadership Presence and Future of Work
Delayed graft function, where a transplanted kidney does not perform adequately immediately after transplant, is a major concern in kidney transplantation and is linked to longer hospital stays, higher costs, and poorer long-term outcomes. Dr. Abraham explained that the preclinical results indicate that room-temperature, oxygenated, pulsatile perfusion may offer an optimal balance between the effectiveness of normothermic perfusion and the cost advantages of cold preservation. He highlighted that this approach maintains a metabolic rate that can be supported by dissolved oxygen without requiring an oxygen carrier while remaining suitable for organ assessment and therapy.
Health Technology Insights: Health Technology Insights: Latest News And Innovations – Roundup 3 February 2026
Dr. Andrew Barbas, Chief Scientific Officer at BMI OrganBank and Associate Professor of Surgery in the Duke Division of Abdominal Transplant Surgery, emphasized that these findings suggest the technology may overcome limitations of traditional cold preservation by keeping kidneys in a physiologically active state. This approach not only supports early graft function but also provides more reliable data for pre-transplant assessment.
The new preclinical evidence builds on prior studies and reinforces the potential of the OrganBank Kidney platform, supporting the FDA Breakthrough Device Designation the technology received in July 2025. BMI OrganBank plans to begin clinical trials for the OrganBank Kidney system later this year, marking an important step toward bringing this innovative preservation technology to clinical use.
Health Technology Insights: TransLogic Launches Secure Tube System Monitoring
To participate in our interviews, please write to our HealthTech Media Room at info@intentamplify.com
